scilogo.jpg
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
July 08, 2024 08:30 ET | SciSparc Ltd
According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
scilogo.jpg
SciSparc Secures Strategic Advantage with Grant of European Patent
May 31, 2024 07:17 ET | SciSparc Ltd
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
scilogo.jpg
SciSparc to Acquire AutoMax
April 11, 2024 08:15 ET | SciSparc Ltd
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
March 27, 2024 08:55 ET | SciSparc Ltd
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
March 21, 2024 08:58 ET | SciSparc Ltd
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
scilogo.jpg
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
March 18, 2024 07:29 ET | SciSparc Ltd
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
March 14, 2024 08:49 ET | SciSparc Ltd
First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients TEL AVIV, Israel, March 14, 2024 (GLOBE NEWSWIRE) --...
scilogo.jpg
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
March 12, 2024 08:14 ET | SciSparc Ltd
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
scilogo.jpg
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
March 08, 2024 07:11 ET | SciSparc Ltd
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
scilogo.jpg
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
March 07, 2024 07:49 ET | SciSparc Ltd
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions TEL AVIV, Israel, March 07, 2024 ...